Life Sciences

  • August 25, 2026

    Lupin Beats Vertex's Patent Suit Over Cystic Fibrosis Drug

    A Delaware federal court has rejected Vertex Pharmaceuticals Inc.'s suit accusing Lupin Ltd. of infringing patents covering a cystic fibrosis treatment, with a judge saying Monday that Lupin's planned generic doesn't have the specific concentration of the drug covered by the patents.

  • August 25, 2026

    Abbott Cuts $88.5M Deal To End Investors' Formula Recall Suit

    Abbott Laboratories and a proposed class of shareholders have reached an $88.5 million settlement to resolve claims that the company misled investors about its safety practices ahead of the 2022 recall at its Sturgis, Michigan, infant formula plant, in a deal that comes a month after an Illinois federal judge tossed the suit upon finding the claims "have no juice."

  • August 25, 2026

    FDA Must Revisit Xifaxan Generic Exclusivity, DC Circ. Says

    The D.C. Circuit on Tuesday ordered the U.S. Food and Drug Administration to take another look at Norwich Pharmaceuticals' bid to bring a generic version of a prescription drug for irritable bowel syndrome to market, faulting the FDA's use of what the court said was an incorrect causation standard.

  • August 25, 2026

    Drugstores Beat Sun Pharma's $10M Racketeering Suit

    A New Jersey federal judge threw out Sun Pharmaceutical Industries Inc.'s suit against a group of pharmacies alleging they engaged in a criminal, years-long racketeering scheme that resulted in it paying more than $10 million in refunds for short-dated pharmaceutical products, ruling that the pharmacies were improperly joined together.

  • August 25, 2026

    McKesson Snags Precision Medicine Group In $2.25B Deal

    Healthcare services provider McKesson Corp., advised by Davis Polk & Wardwell LLP, on Tuesday unveiled plans to acquire clinical research and biopharmaceutical commercialization services business Precision Medicine Group for roughly $2.25 billion.

  • August 25, 2026

    Cooley Life Sciences Atty Joins Foley & Lardner In San Diego

    Foley & Lardner LLP announced that a life sciences attorney with over 30 years of experience has jumped to the firm's San Diego office as a partner from Cooley LLP.

  • August 25, 2026

    Rising Star: Williams & Connolly's Kathryn Kayali

    Kathryn Kayali of Williams & Connolly LLP has helped secure major wins in high-profile pharmaceutical patent litigation over COVID-19 vaccines and played a role in landing the first injunctions under the Biologics Price Competition and Innovation Act, earning her a spot among life sciences lawyers under age 40 honored by Law360 as Rising Stars.

  • August 25, 2026

    Judge Allows Hospital Groups To Fight AbbVie 340B Suit

    A D.C. federal judge will allow hospitals and health center groups to intervene on the side of the government as it fights AbbVie's challenge to the definition of "patient" in the 340B drug discount program, ruling that the providers would suffer concrete financial harm if the pharmaceutical company's interpretation prevails.

  • August 24, 2026

    'So What?': Albertsons Judge Skeptical Of Wash. Opioid Suit

    A Washington state judge considering Albertsons' mid-trial motion to dismiss allegations it fueled the state's opioid epidemic told lawyers for the state Monday that while they might have shown the pharmacy chain failed to implement an adequate monitoring system, she's still skeptical the company's conduct actually caused the overdose crisis.

  • August 24, 2026

    DOJ Seeks To Beat UC Researchers' Challenge Of Grant Axings

    The U.S. Department of Justice argued on Friday that the Trump administration should prevail over University of California researchers' challenges of the termination of their grants, telling a California federal judge that the First Amendment doesn't apply to competitively awarded grants.

  • August 24, 2026

    Biopharma Co. Brass Sued Over 'Channel Stuffing' Disclosures

    The top brass of pharmaceutical company ADMA Biologics Inc., among other things, failed to disclose certain related-party transactions the company engaged in and a channel-stuffing scheme to create the appearance of revenue, according to a shareholder derivative suit filed Monday.

  • August 24, 2026

    Judge Preserves, But Narrows, IP Verdict Against NuVasive

    A Delaware federal judge on Monday kept in place much of a jury's infringement findings against NuVasive in a doctor's case against it over a group of spinal implant patents but found the jury's other infringement conclusions weren't supported by enough evidence.

  • August 24, 2026

    Tribal Opioid Suits Against Sacklers Slated For $175M Exit

    Dozens of Native American tribes have asked an Ohio federal court to dismiss their lawsuits against members of the Sackler family, which owns bankrupt opioid maker Purdue Pharma, based on a settlement agreement that will pay $175 million to the tribes over 16 years.

  • August 24, 2026

    Merck Loses HHS Suit Over Medicare Drug Price Program

    A D.C. federal judge shot down Merck's challenge to the Inflation Reduction Act's Drug Price Negotiation Program on Monday, ruling that the pharmaceutical giant's voluntary participation in connected Medicare and Medicaid programs meant that its inclusion in the negotiation program doesn't constitute an unconstitutional taking.

  • August 24, 2026

    DOJ Backs Biotech Co. Against Red Cross At 1st Circ.

    The U.S. Department of Justice is continuing to back a biotech company that accuses the American Red Cross of blocking competition for blood platelet testing, telling the First Circuit the nonprofit is not part of the government and is not immune from the antitrust claims.

  • August 24, 2026

    Colo. Judge Certifies Class In Hospital Gender Care Suit

    A Colorado state judge granted class certification in transgender adolescents' lawsuit seeking to have Children's Hospital Colorado resume providing gender-affirming medical care for them and other transgender youth patients.

  • August 24, 2026

    DaVita Defeats Nurse Overtime Collective Bid

    A Colorado federal judge refused to conditionally certify a 41-state collective of DaVita nurses and technicians who say the company denied them overtime by failing to pay for short rest breaks, finding too little evidence of a companywide practice.

  • August 24, 2026

    Fed. Circ. Agrees To Speed Up Args In COVID Vax Patent Case

    The Federal Circuit on Monday agreed to accelerate the schedule in a COVID-19 vaccine patent dispute between Moderna and Arbutus Biopharma Corp. by holding arguments in November.

  • August 24, 2026

    3 Firms Build Biotech Merger With $150M In Private Funding

    Biopharmaceutical company Werewolf Therapeutics and clinical-stage biotechnology firm Ambros Therapeutics have agreed to merge in an all-stock deal built by three law firms, and includes $150 million in private funding.

  • August 24, 2026

    Judge Orders $245M In Guardant Damages In DNA Patent Suit

    A judge has boosted what Guardant Health Inc. owes in a case in which it was found to have infringed two TwinStrand Biosciences Inc. patents covering methods of lowering the error rate in DNA sequencing, bringing the total to $245 million.

  • August 24, 2026

    Rising Star: Paul Weiss' Benjamin Goodchild

    Benjamin Goodchild of Paul Weiss Rifkind Wharton & Garrison LLP developed an innovative deal structure while guiding obesity drug developer Metsera Inc. through a tumultuous bidding war that resulted in its acquisition by Pfizer Inc., earning him a spot among the life sciences law practitioners under age 40 honored by Law360 as Rising Stars.

  • August 24, 2026

    Catching Up With Delaware's Chancery Court

    The Delaware Chancery Court last week saw a wave of lawsuits involving corporate oversight, take-private deals, financing transactions, bankruptcy fallout, stockholder voting rights and disputes over control.

  • August 21, 2026

    Cytek Hit With $56M Verdict For Infringing Cell-Sorting Patent

    A Delaware federal jury Friday awarded roughly $36 million in damages to biomedical testing manufacturer Beckman Coulter after finding that Cytek Biosciences infringed one of its patents covering a technology that quickly analyzes single cells.

  • August 21, 2026

    Trump Seeks Justices' Review Of DEI Grant Termination Case

    The Trump administration is urging the U.S. Supreme Court to review a Ninth Circuit decision requiring the federal government to reinstate research grants that were terminated due to presidential orders against diversity, equity and inclusion initiatives.

  • August 21, 2026

    Pharma Co. Loses Challenge To $3M Acne Drug Arb. Award

    A New York federal court confirmed an arbitrator's finding that Sun Pharmaceuticals breached an agreement with the owner of an acne drug by seeking regulatory approval to market a version of the drug in Canada, rejecting arguments that the arbitrator wrongly relied on extrinsic evidence.

Expert Analysis

  • How 'Most Favored Nation' Regime Affects Biopharma Deals

    Author Photo

    As M&A activity surges in the biopharma space, companies will need to account for the Trump administration's most-favored-nation pricing proposals — durable in concept, if unsettled in detail — when drafting deals, say attorneys at Gibson Dunn.

  • What To Know As Legal Duty To Consider AI Takes Shape

    Author Photo

    While the U.K. Jurisdiction Taskforce’s recent statement on liability for artificial intelligence harms is nonbinding for both U.K. and U.S. lawyers, it highlights the importance of being able to distinguish between the availability of a tool and a professional obligation to use it, say Jonny Frank and Michael Costa at StoneTurn.

  • NC Dental Review Change Counters Tougher National Trend

    Author Photo

    North Carolina’s elimination of its prior review requirement for dental management agreements departs sharply from the national trend toward expanded corporate practice of medicine oversight, but stakeholders should not view this regulatory shift as a relaxation of compliance expectations, say attorneys at Holland & Knight.

  • NY Bill Would Boost Litigation Risk For Cosmetics Cos.

    Author Photo

    The Beauty Justice Act, now pending in the New York Legislature, would not only present compliance challenges for companies making cosmetics and personal care products, but could also be used by private plaintiffs to bring consumer fraud, false advertising, toxic exposure and product liability claims, says Kadeejah Kelly-Previl at Faegre Drinker.

  • How To Structure Protective Order AI Provisions In IP Disputes

    Author Photo

    A survey of protective orders in recent intellectual property litigation reveals best practices for drafting provisions on artificial intelligence use that maximize IP protection while balancing enforceability with efficient discovery, say Matthew Stephens and Bryce Tabbut at MoFo.

  • Appellate Vape Rulings May Expand State Regulation Powers

    Author Photo

    Two recent federal appeals courts decisions rejecting Federal Food, Drug and Cosmetic Act preemption challenges to state electronic nicotine delivery systems directory laws signal an emerging appellate consensus that could significantly expand states' power to regulate vaping product sales where federal enforcement falls short, say attorneys at Troutman.

  • 5 Lessons For VC Investors From Del. IPO Ruling

    Author Photo

    The Delaware Court of Chancery's recent dismissal of Rostov v. Alcon Research, a derivative action over a proposed initial public offering, provides multiple practice pointers for venture capital investors, including the importance of precisely worded corporate documents and pleading a coherent theory of corporate harm, says Ben Dubin at VC Expert Services.

  • Fed. Circ. Rulings Emphasize Adjudicative Access And Review

    Author Photo

    Decisions from the Federal Circuit's 2026 docket indicate that the court is increasingly paying attention to whether tribunals possess authority to act, meaning practitioners will need to properly address procedural hurdles before they can argue the merits of a case, say attorneys at Reichman Jorgensen.

  • Series

    Being In A Band Made Me A Better Lawyer

    Author Photo

    Playing shows in storied New York City venues and rehearsing with my bandmates in poorly ventilated rooms helped develop the professional qualities I rely on as a litigator, including an ability to collaborate with strong-minded equals and the determination to treat each client with singular focus, says Eliad Shapiro at Herrick Feinstein.

  • 10th Circ. Ruling Undermines False Ad 'Two Clicks' Rule

    Author Photo

    The Tenth Circuit’s recent ruling in KetoNatural Pet Foods v. Hill's Pet Nutrition substantially challenges a long-standing assumption that a company can avoid responsibility for promotional claims simply because the consumer encountered them by clicking a hyperlink to a third-party website, say attorneys at Venable.

  • How Drug Trial Prediction Markets Pose Insider Trading Risks

    Author Photo

    Multiple prediction market platforms have recently announced plans to offer event contracts related to clinical trial outcomes and regulatory decisions, creating new insider trading risks by expanding the group of people possessing related material nonpublic information far beyond traditional corporate insiders, say attorneys at King & Spalding.

  • Mich. Ruling Gives Consumer Protection Law Its Teeth Back

    Author Photo

    The Michigan Supreme Court's recent decision in Attorney General v. Eli Lilly, overruling key holdings in two earlier cases, means that Michigan businesses can no longer defeat allegations of deceptive conduct under the state's consumer protection law simply by pointing to any governmental regulation of the business, say attorneys at DiCello Levitt.

  • Series

    Law School's Missed Lessons: Surviving A Long Trial

    Author Photo

    Most of law school trial advocacy is geared toward the sprint of trying a short case, but beyond managing a cross-examination or closing argument, effectively handling the marathon of a lengthy trial requires the ability to maintain composure, organization and credibility with the jury, says Mihir Elchuri at Hirschler.

  • AI Chatbot's Medical Claims Highlight Enforcement Risks

    Author Photo

    The Pennsylvania State Board of Medicine's recent lawsuit against Character Technologies, arguing that an artificial intelligence chatbot engaged in the unlicensed practice of medicine, may provide other state licensing boards with a road map for going after AI platforms, and counsel should advise clients to calibrate compliance accordingly, say attorneys at Cooley.

  • 7th Circ. Ruling May Reduce Litigation Risk For Text Marketers

    Author Photo

    The recent Seventh Circuit holding in Steidinger v. Blackstone Medical Services that unwanted marketing text messages are not telephone calls under the Telephone Consumer Protection Act may strengthen companies' responses to presuit demand letters and early-stage litigation claims premised on do-not-call text theories, say attorneys at Holland & Knight.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here